About Dongwen Lyu
Dr. Dongwen Lyu (Lv) joined University of Florida as a research assistant professor in department of pharmacodynamics in May 2019. He has published 32 peer-reviewed papers of which he was the first or co-first author on 15 of the publications. He received extensive training during his PhD study in proteomics and bioinformatics. He completed his first Postdoc training in Virginia Commonwealth University to study EBV reactivation. His studies revealed that interferon regulatory factor 8 (IRF8) plays an important role in regulation of EBV. In 2017, he joined Dr. Daohong Zhou’s lab as a Postdoc associate to elucidate the molecular mechanism by which proteolysis targeting chimeras (PROTACs). The new insights will direct the designing of better PROTACs that can selectively kill senescent cells and cancer cells, which have the potential to be used as novel anti-aging and cancer agents.
Dr. Dongwen Lyu (Lv)’s research focuses on two major directions. The first direction is investigation of the cellular and molecular mechanisms of aging and aging related diseases and discovery of new senolytic drugs which can selectively kill senescent cells. The second direction is further elucidating the molecular mechanism of proteolysis targeting chimeras (PROTACs) that can target proteins of interest for degradation via the ubiquitination and proteasome system and design of more potent and safer PROTACs to selectively kill senescent cells and cancer cells.